FSH and bone--important physiology or not?
For many years, osteoporosis in women was equated with estrogen deficiency. The recent articles by Zaidi and colleagues offer a new challenge to the estrogen-deficiency-osteoporosis hypothesis by showing that follicle-stimulating hormone (FSH) stimulates osteoclastic bone resorption perhaps through tumor necrosis factor-alpha (TNF-alpha). These authors, however, neglected to mention bone abnormalities and high testosterone levels that were previously shown in FSH-receptor knockout and other modified mice. It is also possible that they have overemphasized potential relationships of these new data with human bone loss. Despite these fascinating data, the paradigm of FSH causing hypogonadal bone loss is not yet ready to displace the estrogen-deficiency-osteoporosis paradigm, although that model already faces considerable challenge.
Prior
Jerilynn C
JC
Endocrinology and Metabolism, Centre for Menstrual Cycle and Ovulation Research, University of British Columbia, Vancouver Coastal Health Research Institute, Vancouver V5Z 1M9, Canada. jerilynn.prior@vch.ca
D001862:Bone Resorption / Q000209:etiology* / Q000378:metabolism; D004967:Estrogens / Q000172:deficiency*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000378:metabolism*; D006801:Humans; D008954:Models, Biological; D015663:Osteoporosis, Postmenopausal / Q000209:etiology*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D004967:Estrogens; D014409:Tumor Necrosis Factor-alpha; D005640:Follicle Stimulating Hormone